Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Double plant homeodomain finger 2 (DPF2) is a highly conserved transcription factor and chromatin regulator that contains a C2H2-type zinc finger domain and tandem plant homeodomain (PHD) finger motifs, enabling it to bind to and “read” specific acetylation and crotonylation marks on histones H3 and H4[1][2][3][4]. Through these interactions, DPF2 integrates into multi-protein complexes, notably the SWI/SNF chromatin remodeling complex, and modulates the transcription of target genes—often repressing myeloid differentiation by forming repressive complexes on specific promoters (such as miR-223) and regulating pathways such as non-canonical NF-κB signaling[1][2][3][4]. DPF2 is implicated in the pathogenesis of hematological malignancies (such as leukemia), development of lymphoid cells, and rare congenital syndromes like Coffin-Siris syndrome 7[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Double plant homeodomain finger 2 (DPF2).